+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Psoriatic Arthritis Pipeline Analysis and Outlook, 2019

  • ID: 4772526
  • Report
  • May 2019
  • Region: Global
  • 159 pages
  • VPA Research
1 of 3


  • 3SBio Inc
  • Akeso Biopharma Inc
  • Eli Lilly and Co
  • Innovent Biologics Inc
  • Novartis Pharmaceuticals
  • Rigel Pharmaceuticals Inc
  • MORE
Psoriatic Arthritis pipeline

Psoriatic Arthritis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Psoriatic Arthritis R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Psoriatic Arthritis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Psoriatic Arthritis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Psoriatic Arthritis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Psoriatic Arthritis pipeline Profiled in detail

Key players actively participating in Psoriatic Arthritis pipeline are profiled along with their R&D progress in Psoriatic Arthritis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Psoriatic Arthritis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Psoriatic Arthritis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Psoriatic Arthritis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Psoriatic Arthritis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Psoriatic Arthritis pipeline study
  • All recent news and developments related to Psoriatic Arthritis drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • 3SBio Inc
  • Akeso Biopharma Inc
  • Eli Lilly and Co
  • Innovent Biologics Inc
  • Novartis Pharmaceuticals
  • Rigel Pharmaceuticals Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Psoriatic Arthritis Disease Overview

3. Psoriatic Arthritis Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Psoriatic Arthritis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Psoriatic Arthritis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Psoriatic Arthritis companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Psoriatic Arthritis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • 3SBio Inc
  • AbbVie Inc
  • AbGenomics International Inc
  • Aclaris Therapeutics Inc
  • Adello Biologics LLC
  • Agragen LLC
  • Akeso Biopharma Inc
  • Amgen Inc
  • Biocad
  • Biocon Ltd
  • Coherus BioSciences Inc
  • DNX Biopharmaceuticals Inc
  • Eli Lilly and Co
  • Formycon AG
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Harvest Moon Pharmaceuticals
  • Immunwork Inc
  • Innovent Biologics Inc
  • Innovimmune Biotherapeutics
  • Johnson & Johnson
  • Kv1.3 Therapeutics
  • Morphotek Inc
  • Mycenax Biotech Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Novartis Pharmaceuticals
  • Nuevolution AB
  • Numab Innovation AG
  • Oncobiologics Inc
  • Pfizer Inc
  • Rigel Pharmaceuticals Inc
  • Sandoz International GmbH
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • SynAct Pharma AB
  • UCB SA
  • Vitaeris Inc
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown